Epcoritamab monotherapy or epcoritamab with lenalidomide as first-line therapy for patients with diffuse large B-cell lymphoma (EPCORE DLBCL-3): primary analysis of an open-label, multicentre, randomised, phase 2 trial.
AuteursVitolo U, Burgues JMB, Duell J, Kwiatek M, Belada D, Jurczak W, Maerevoet M, Sibon D, Greil R, Kumode T, López-Jimenez J, Meert C, Cia JS, Thieblemont C, Alcaide SO, Kim WS, Cordoba R, Wielgos-Bonvallet M, Jiang T, Wang Y, McGoldrick S, Guo E, Morschhauser F, Woei-A-Jin FJSH
The role of the 21-gene assay in the neoadjuvant setting for hormone receptor-positive HER2-negative breast cancer: Impact on systemic and surgical treatment decisions.
AuteursZotano ÁG, Allweis TM, Foerster R, Palmieri C, Gluz O, Chia S, Sotiriou C, Bianchini G
Organ at risk sparing by non-coplanar prone breast radiotherapy on Halcyon/Ethos linacs utilizing breast couch slewing.
AuteursSpeleers B, Stouthandel MEJ, Vakaet V, Paelinck L, Schoepen M, Van Greveling A, Van Esch A, Wéra AC, Remouchamps V, Van Hoof T, Veldeman L, De Gersem W, De Neve W
Luminal-basal stratification of the native human pancreatic duct is differentially represented in pancreatic cancers.
AuteursVan den Bossche JL, Van der Vliet M, Michiels E, Azurmendi Senar O, Van Lint S, Madran Z, Coolens K, Brons J, Nacher M, Arsenijevic T, Messaoudi N, Lefesvre P, Bouchart C, Verset L, Navez J, Fallas J, Dusetti N, Montanya E, Rovira M, Van Laethem JL, Houbracken I, Baldan J, Rooman I
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
AuteursDe Caluwé A, Desmoulins I, Cao K, Remouchamps V, Baten A, Longton E, Peignaux K, Joaquin Garcia A, Venet D, Arecco L, Agostinetto E, Nader-Marta G, Denis Z, Dhont J, Kristanto P, Catteau X, Larsimont D, Salgado R, Poortmans P, Stagg J, Sotiriou C, Piccart M, Ignatiadis M, Romano E, Buisseret L
